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ABSTRACT
Purpose: Preclinical tumor models show that chemotherapy has immune 
modulatory properties which can be exploited in the context of immunotherapy. 
The purpose of this study was to determine the feasibility and immunogenicity 
of combinations of such an immunomodulatory chemotherapeutic agent with 
immunotherapy, p53 synthetic long peptide (SLP) vaccine and Pegintron (IFN-α) in 
patients with platinum-resistant p53-positive epithelial ovarian cancer (EOC).
Experimental design: This is a phase 1/2 trial in which patients sequential 6 cycles 
of gemcitabine (1000 mg/kg2 iv; n = 3), gemcitabine with Pegintron before and after the 
first gemcitabine cycle (Pegintron 1 μg/kg sc; n = 6), and gemcitabine and Pegintron 
combined with p53 SLP vaccine (0.3 mg/peptide, 9 peptides; n = 6). At baseline, 22 
days after the 2nd and 6th cycle, blood was collected for immunomonitoring. Toxicity, 
CA-125, and radiologic response were evaluated after 3 and 6 cycles of chemotherapy.
Results: None of the patients enrolled experienced dose-limiting toxicity. Predominant 
grade 3/4 toxicities were nausea/vomiting and dyspnea. Grade 1/2 toxicities consisted 
of fatigue (78%) and Pegintron-related flu-like symptoms (72%). Gemcitabine reduced 
myeloid-derived suppressor cells (p = 0.0005) and increased immune-supportive M1 
macrophages (p = 0.04). Combination of gemcitabine and Pegintron stimulated higher 
frequencies of circulating proliferating CD4+ and CD8+ T-cells but not regulatory T-cells. 
All vaccinated patients showed strong vaccine-induced p53-specific T-cell responses.
Conclusion: Combination of gemcitabine, the immune modulator Pegintron and 
therapeutic peptide vaccination is a viable approach in the development of combined 
chemo-immunotherapeutic regimens to treat cancer.
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INTRODUCTION
Ovarian cancer has a dismal prognosis, with a 
5-years survival of 30% [1, 2]. These cancer patients 
are treated with platinum-based chemotherapy but the 
majority develops recurrences and ultimately die because 
of treatment failure, indicating that other treatment 
strategies are warranted. Cancer immunotherapy has been 
shown to be an effective treatment modality in metastatic 
cancer, however, clinical efficacy is often delayed and 
only observed in a part of the treated cancer patients [3], 
including those with ovarian cancer [4, 5]. Epithelial 
ovarian cancer (EOC) is likely to benefit from T-cell-based 
immunotherapy as it was observed that strong infiltration 
with CD8+ T-cells is correlated with enhanced survival 
and response to chemotherapy [6, 7]. Unfortunately, the 
EOC microenvironment is known to restrain the cytotoxic 
activity of effector lymphocytes in a direct fashion [8, 9] 
as well as indirectly by favoring the accumulation of 
regulatory T-cells (Tregs), myeloid-derived suppressor 
cells (MDSC) and M2 macrophages [10–12], associated 
with suppression of tumor immunity and treatment failures 
[13]. The path to clinical success in patients with EOC 
thus requires a strategy that increases the frequency and 
activity of antitumor T-cells while eliminating suppressive 
immune cells and providing enough time for a fully 
developed antitumor response, hence treatment should 
start as early as possible.
In the last decade, platinum-resistant EOC patients 
are often treated with gemcitabine as it has single agent 
activity and a favorable safety profile [14]. Interestingly, 
gemcitabine not only has direct anti-tumor effects but 
has also been shown to eliminate MDSCs and Tregs 
in preclinical tumor models [15–18]. In addition, we 
showed that gemcitabine delayed tumor growth and 
synergized with therapeutic vaccination for the eradication 
of established tumors in a murine tumor model [19]. 
Altogether, in preclinical studies gemcitabine could 
not only be successfully combined with therapeutic 
vaccination but it also deleted two types of immune 
suppressive cells playing a role in EOC.
Based on these preclinical data we hypothesized 
whether it was possible to combine gemcitabine with 
therapeutic vaccination and interferon alpha (IFN-α) 
in patients. In this study, we chose to use the p53 
Synthetic Long Peptide vaccine (P53 SLP) to strengthen 
the tumor-specific immune response [20]. The p53 
protein is overexpressed in about half of the ovarian 
cancer patients and known to activate spontaneous 
T-cell responses in these patients [21]. Previously, 
administration of the p53 SLP vaccine in patients 
with ovarian cancer was feasible, safe and showed to 
induce p53-specific T-cell responses [22]. Treatment 
with a low dose of cyclophosphamide to temporary 
decrease the number of Tregs, given before p53 SLP 
vaccination further increased the p53-specific immune 
responses, but did not improve clinical responses [23]. 
In colorectal cancer patients the combination of this p53 
SLP vaccine with IFN-α on the injection site resulted in 
enhanced inflammation as well as stronger and better 
type 1 cytokine polarized p53-specific CD4+ and CD8+ 
T-cell responses [24]. IFN-α is known to induce the 
full maturation of dendritic cells, to improve cross-
presentation of tumor antigens and to enhance survival 
of activated T-cells, thereby enhancing the anti-tumor 
response [25–30]. In preclinical mouse experiments, no 
tolerance of CD4+ T-cells to wt p53 was demonstrable 
[31, 32] and such CD4+ T-cells enhanced the anti-tumor 
effect of tumor-specific CD8+ T-cells [31].
Here, we studied the feasibility and 
immunogenicity to treat patients with platinum-resistant 
p53-positive ovarian cancer using combinatorial 
regimens in which p53 SLP vaccination and Pegintron 
(IFN-α) were administrated before and after the 
first cycle of gemcitabine. Analysis of the effect of 
these compounds on the patient’s immune system 
revealed a reduction in MDSC, an increase in both M1 
macrophages and activated T-cells, as well as a strong 
reactivity against the p53 SLP vaccine.
MATERIALS AND METHODS
Patients
Patients were eligible for inclusion in the study 
if they were at least 18 years of age, had platinum-
resistant ovarian cancer with immunohistochemically 
confirmed ‘mutant’ p53-expression pattern, defined as 
a strong nuclear staining in more than 75% of the tumor 
cells, had measurable disease (RECIST 1.1) or elevated 
CA-125 > 2 times the upper limit. Patients also had to 
have a WHO performance score of 0–2 and adequate 
bone marrow function (WBC ≥3.0 × 109/L, neutrophils 
≥ 1.5 × 109/L, platelets ≥100 × 109/L), liver function 
(bilirubin ≤1.5 × upper limit of normal (UNL) range, 
ALAT and/or ASAT ≤2.5 × UNL, Alkaline Phosphatase 
≤5 × UNL) and renal function (calculated creatinine 
clearance ≥50 mL/min). Written informed consent 
was obtained from all patients. Patients were excluded 
from the study when they had a malignancy within 
the previous 5 years (with exception of a history of a 
previous basal cell carcinoma of the skin or pre-invasive 
carcinoma of the cervix), serious other diseases, known 
hypersensitivity to any of the components of the 
treatment, were pregnant or lactating or had any medical 
or psychological condition which in the opinion of the 
investigator would not permit the patient to complete 
the study or sign meaningful informed consent. The 
study was ethically approved by the Central Committee 
on Research Involving Human Subjects in The Hague, 




Primary objective was to determine the feasibility 
and immunogenicity of the combination of gemcitabine 
and interferon alpha-2b with or without p53 SLP. To 
assess the primary endpoint of feasibility, the incidence 
and severity of all adverse events, vital parameters and 
changes in blood chemistry and hematology parameters 
were determined. Toxicity was measured using the 
Common Terminology Criteria for Adverse Events v4.03 
(CTCAEv4.03). Relationship to treatment was evaluated 
for all adverse events. At each visit, patients were 
assessed by physical examination, vital signs, toxicity 
and complete blood count with differential and serum 
biochemistry. The immunogenicity was determined 
by assessment of the induction of p53-specific T-cells 
following treatment. Secondary endpoints were 
assessment of the effect of chemo-immunotherapy 
on the immune system and the relationship between 
anti-tumor immunity and clinical outcome. The effect 
on the immune system was measured by an array 
of immunologic assays as described below (see: 
immunomonitoring). Tumor response to treatment was 
evaluated according to gynecological cancer intergroup 
(GCIG) criteria [33] by combining serum CA-125 levels 
obtained at every visit with computerized tomography 
(CT) performed within three weeks after third and sixth 
cycle of chemotherapy and evaluated according to 
RECIST criteria 1.1 [34].
Treatment schedule
This was an open-label, multi-center, sequential 
trial. All patients received standard chemotherapy, 6 
cycles of gemcitabine 1000 mg/m2 iv (d1, 8, 15; every 
4 weeks). Patients were sequentially treated in three 
groups: the first three patients received gemcitabine 
alone, the following six patients received gemcitabine and 
IFN-α 2b s.c. (Pegintron 1 μg/kg, Schering-Plough, The 
Netherlands) 7 days prior and 22 days after to the first 
infusion of gemcitabine . The last cohort of six patients 
received gemcitabine, Pegintron and additionally p53 SLP 
vaccine (0.3 mg.peptide) in the same treatment schedule 
(Figure 1). The Pegintron as well as the vaccination were 
injected in the upper arm; Pegintron was injected within 10 
centimeters proximity to the vaccination site. At baseline, 
day 22 of second cycle gemcitabine and at the end of 
the study, blood was drawn for immune-monitoring. To 
evaluate the impact of treatment on the immune system 
at least 5 evaluable patients (defined by a blood sample 
taken before and after treatment) were required in every 
intervention group.
Vaccine
The p53 SLP vaccine consisted of 9 synthetic 
25–30 amino acids long overlapping peptides, spanning 
amino acids 70–235 of the wt-p53 protein. Peptides 
were prepared at the GMP facility of the Department 
Figure 1: Study scheme. This study consisted of three treatment groups: 1. 3 patients receiving only gemcitabine; 2. 6 patients receiving 
gemcitabine and Pegintron; 3. 6 patients receiving gemcitabine, Pegintron and p53 SLP. Before, after 2 cycles and after the last cycle, blood 
was drawn for immunomonitoring. Tumor assessment was performed at baseline, after 3 and after 6 cycles. *Pegintron was given 7 days 
prior to the first dose of gemcitabine and day 22 (Group 2). **The combination Pegintron and p53 SLP® 7 days prior to the first dose of 
gemcitabine and day 22 (Group 3).
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of Clinical Pharmacy and Toxicology at the LUMC. At 
the day of immunization the peptides (0.3 mg/peptide) 
were dissolved in dimethyl sulfoxide (DMSO, final 
concentration 20%) admixed with 20 mM phosphate 
buffer (pH 7.5) and emulsified with an equal volume of 
Montanide ISA-51 (Seppic). At the day of vaccination, the 
vaccine was prepared as previously described [24]. The 
vaccine (2.7 mL) was administered subcutaneously in the 
upper arm.
Expression of p53
The expression of p53 by ovarian tumor cells was 
determined in the available paraffin-embedded metastatic 
tissue of the vaccinated patients by standard two-step 
indirect immunohistochemical staining as described 
previously [20]. Strong nuclear expression of p53 in ≥75% 
of the tumor cells was considered positive.
Immunomonitoring
We acknowledge the concept of the Minimal 
Information About T-cell Assays (MIATA) reporting 
framework for human T-cell assays [35].
Cell samples
Venous blood (80 cmL) samples were drawn prior 
to vaccination, three weeks after the second chemotherapy 
cycle and at the end of study (three weeks after the 
sixth cycle of chemotherapy or if previously stopped 
at end of study). Peripheral blood mononuclear cells 
(PBMCs) and blood serum were isolated and stored as 
described previously [24]. To compare patient’s immune 
characteristics with healthy donors, blood of six age-
matched healthy donors was collected, processed and 
stored identically.
Enzyme linked immunospot (ELISPOT) assay
PBMCs prior to and post vaccination were thawed 
at the same time and subjected to the assay as described 
previously [24]. Briefly, a set of six pools of long 
overlapping peptides, indicated by the first and last amino 
acid in the p53 protein, was used for the screening of T-cell 
responses: p53.1: 1–78; p53.2: 70–115; p53.3: 102–155; 
p53.4: 142–203; p53.5: 190–248; and p53.6: 241–393. 
Peptide pools p53.2 to p53.5 represented the sequence 
in the p53 protein included in the vaccine, whereas the 
other two peptide pools p53.1 and p53.6 represented the 
remaining and flanking parts of p53. As a positive control, 
recall antigen mixture, the memory response mix (MRM), 
was taken along. Memory Response Mix (MRM; stock 
4 ×), consisting of tetanus toxoid (0.06 LF/mL; National 
Institute of Public Health and the Environment, Bilthoven, 
The Netherlands), mycobacterium tuberculosis sonicate 
(0.4 μg/mL; Royal Tropical Institute, Amsterdam, The 
Netherlands) and Candida Albicans (0.0012%; HAL 
Allergenen Lab, Haarlem, The Netherlands).
The plates were read by automated ELISPOT reader 
(BioSys, Karben, Germany) according to guidelines as 
published [36]. Specific spots (mean number of spots in 
the test wells minus the mean number of spots plus 2x 
standard deviation (STD) in medium only control wells) 
of at least 1 in 10,000 PBMCs is considered a positive 
antigen-specific T-cell response. A vaccine-induced 
response was defined as at least a 3-fold increase in 
response after vaccination compared with the baseline 
sample.
Analysis of lymphocyte proliferation assay
The proliferative capacity of T-cells to mitogenic 
stimulation was analyzed as described previously [20]. 
The mean plus 3x STD of 4 medium control wells was 
used as cut-off value. The stimulation index (SI) was 
calculated by dividing the mean of test wells by that 
of the control wells. A positive response was defined 
as SI ≥ 3.
Antigen presenting cell capacity
PBMCs were tested in a mixed lymphocyte reaction 
(MLR) to evaluate the antigen presenting capacity as 
described before [24].
Immunophenotyping by flow cytometry
The immune cell composition of PBMCs was 
analyzed by flow cytometry as described previously [37]. 
Gating strategies are shown in Supplementary Figure S1. 
In short, a million cells were spin down and afterwards, 
1mL lysisbuffer was added for 1 minute. After addition 
of 9 mL IMDM + 10% fetal cow serum (FCS), cells were 
centrifuged and staining was performed in PBS/0·5% 
BSA. Fc-receptor was blocked 10 minutes on ice by 
adding 50 μl PBS/0·5% BSA/10% FCS. Cells were 
incubated for 30 minutes with a mixture of the following 
antibodies: CD1a (FITC, clone HI149 – BD, Breda, 
The Netherlands), CD3 (Pacific Blue, clone UCHT1 
– DAKO, Heverlee, Belgium or V450, clone UCHT1 
– BD), CD4 (Horizon V500, clone RPA-T4 – BD), 
CD8 (APC-Cy7, clone SK1 – BD), CD11b (PE, clone 
D12 – BD or Alexa Fluor (AF) 488, clone CBRM1/5 – 
Biolegend, Uithoorn, the Netherlands), CD11c (AF700, 
clone B-ly6 – BD), CD14 (FITC, clone M5E2 – BD or 
PE-Cy7, clone M5E2 – BD or AF700, clone M5E2 – 
BD), CD15 (PE CF594, clone W6D3 – BD), CD16 (PE 
CF594, clone 3G8 – BD), CD19 (Brilliant Voilet (BV) 
605, clone SJ25C1 – BD), CD33 (AF700, clone WM53 
– BD or PE-Cy7, cloneP67·7 – BD), CD34 APC, clone 
581 – BD), CD45 (PerCP-Cy5·5, clone 2D1 – BD), CD 
56 (APC-Cy7 – Biolegend), CD124 (IL-4R; PE, clone 
HiL4R-M57 – BD), CD126 (IL-6R; PE, clone M5 – 
BD), CD163 (APC, clone 215927 – R&D, Systems, 
Minneapolis, MN), CD206 (Mannose Receptor; APC-
Cy7, clone 15–2 – Biolegend), LIVE-DEAD® Fixable 
yellow dead cell stain kit (Q-dot585 – Life technologies, 
Oregon, USA), HLA-DR (V500, clone L243 – BD), 
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pSTAT1 (PE, clone py701 – BD), pSTAT3 (AF647, 
clone 49 – BD), pSTAT5 (PE, clone pY694 – BD), 
pSTAT6 (AF648, clone 18 – BD). The data were acquired 
on a the Fortessa (BD) and analysed with DIVA software 
version 6.2 and FlowJo version 7.0.
For the detection of Tregs 1 million PBMC were 
used per condition. Cell surface antibody staining 
of PBMC was performed in PBS/0·5%/BSA/0·02% 
sodium-azide (PBA) buffer for 30 minutes at 4°C. 
Intracytoplasmic/intranuclear staining was conducted 
with the BD Pharmingen Transcription Factor Buffer set 
(BD) according to manufacturers’ protocol. The antibodies 
used are: CD3 (V500, clone UCHT1 – BD), CD4 (AF700, 
clone RPA-T4 – BD), CD25 (PE-CY7, clone 2A3 – BD), 
CD127 (BV650, clone HIL-7R-M21 – BD), CD45RA 
(APC-H7, clone HI100 – BD), CD8 (PerCPCy5·5, clone 
SK1 – BD), FoxP3 (PE-CF594, clone 256D/C7 – BD), 
CTLA-4 (BV421, clone BNI3 – BD), Ki67 (FITC, clone 
20Raj1 – eBiosciences, Vienna, Austria), Helios (APC, 
clone 22F6 – Biolegend) and LIVE-DEAD® Fixable 
yellow dead cell stain kit (Q-dot585). The data were 
acquired on a the Fortessa (BD) and analysed with DIVA 
software version 6.2.
Determination of cytokines
IL-1β, IL-8, IL-10, TNF-α, IL-12p70 Inflammatory 
cytometric bead array (CBA, BD Biosciences) was used to 
determine cytokines and concentration (in pg/mL) present 
in supernatant of above described assays according to the 
manufacturer’s instructions [32].
Laboratory environment
The immunomonitoring assays were performed in 
the laboratory of the department of Medical Oncology 
(LUMC) that operates under research conditions, 
externally and internally audited with respect to 
immunomonitoring, following SOPs, with pre-established 
definitions of positive responses and using trained staff. 
This laboratory has participated in all proficiency panels 
of the CIMT Immunoguiding Program (CIP; of which 
SHvdB and MW are steering committee members; http://
www.cimt.eu/workgroups/cip/) to validate its SOPs as 
well as many of the proficiency panels of the USA-based 
Cancer Immunotherapy Consortium (CIC of the Cancer 
Research Institute).
Statistical analysis
Based on our previous studies [20, 22], a sample 
size of six patients in each intervention group was 
sufficient to measure p53-specific reactions and the 
effect on Pegintron. No further power calculation was 
performed, since this was an exploratory study. For each 
individual immune-modulatory assay, a positive response 
is predefined per assay and described previously. 
Statistical analyses were conducted in SPSS (version 20 
for Windows; SPSS, Inc). The Mann-Whitney test and 
the Fisher’s exact test were used to evaluate differences 
in patient characteristics at different time points. The 
relationship between anti-tumor immunity and clinical 
outcome was determined using t-test and correlation tests 
(Pearson/Spearman). Survival curves were calculated 
using Kaplan-Meier method. Because this is a dose-
finding, hypothesizing generating study, the data is not 
corrected for multiple comparisons.
RESULTS
Patient characteristics
Eighteen patients (median age 61 years, range 
51–69) were enrolled between January 2010 and 
March 2013 in two Dutch hospitals (Leiden University 
medical Center (LUMC) and University Medical 
Center Groningen (UMCG). Patient characteristics are 
shown in Table 1. The mean time from diagnosis until 
inclusion was 31.4 months with a median of 2 (range 
1–5) previous chemotherapy lines. Five patients ended 
the study before the second blood acquisition was 
achieved due to progression of disease. To determine 
the impact of treatment on the immune system in every 
therapy group, three more patients (C16, C17 and 
C18) were enrolled in the second group (gemcitabine 
+ Pegintron). One patient (C08) received only one 
injection of Pegintron because of adverse events (flu-
like symptoms grade 2) and one patient (C12) received 
only one vaccination and Pegintron injection, due to 
adverse events (redness of arm >10 cm and flu-like 
symptoms grade 2; Table 2).
Safety and tolerability
Adverse events
All adverse events are depicted in Table 2A. Nine 
patients (50%) showed grade 3 or 4 adverse events 
(Table 2A). The most frequent grade 3 or 4 adverse events 
were nausea/vomiting (22%) and dyspnea (17%). Four 
patients were admitted to the hospital because of severe 
nausea and vomiting. One patient had severe abdominal 
pain (unknown cause) which resolved spontaneously. 
Three patients had severe dyspnea due to their disease 
of which one had progressive disease and two could 
continue treatment after drainage of pleural fluid. The 
non-neutropenia fever was due to a nephrodrain induced 
Klebsiella pneumonia. No significant changes between the 
different treatment groups were found. One patient of the 
control group presented with a severe hypokalemia; in the 
group of gemcitabine combined with Pegintron one patient 
suffered from a grade 3 hyperkalemia.
The majority of patients experienced fatigue during 
treatment (78%), flu-like symptoms (72%) and nausea/
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Table 1: Patient characteristics and outcome
ID Age WHO FIGO stage Histology Time
Current 
treatment










C01 65 1 IIIc Sereus 14 Third line 3 n n PD PD 9 15
C02 55 2 IV Sereus 18 Third line 1
75% 
(1) n n PD na 5 5
C03 53 1 IV Sereus 14 Third line 6
75% 
(3) n n SD PD 16 73
Gemcitabine + Pegintron
C04 59 1 IIIc Sereus 13 Second line 1 n y
‡ na na 4 9
C05 68 1 IIIc Sereus 4 Second line 2 n y na na 12 17
C06 67 0 III Sereus 63 Sixth line 3 n y PD SD 10 11
C07 55 1 IV Sereus 22 Third line 2 n y PD na 6 7





‡ PD SD 13 23
C09 65 0 III Sereus 30 Fifth line 1 n y PD na 7 8
C16 58 1 IIIc Sereus 22 Third line 3
75% 
(1) n y PD PR 11 ongoing
C17 69 1 IIIc Sereus 12 Second line 6
75% 
(1) n y SD CR 60 ongoing
C18 67 0 IIb Sereus 38 Third line 2
75% 
(1) n y SD nd 13 58
Gemcitabine + Pegintron + p53 SLP®
C10 57 1 IIIc Sereus 22 Third line 3
75% 
(1) y y PD PD 13 39
C11 65 0 IIIc Endome trioid 17
Third 
line 3 y y PD PD 11 25
C12 58 1 IIIc Sereus 11 Second line 3
50% 
(1) y
¥ y PD PD 11 37
C13 69 0 IV Sereus 93 Third line 6 y y SD PR 20 48
C14 57 1 IV Sereus 107 Sixth line 6
80% 
(4) y y PR PR 36 ongoing
C15 58 1 IV Sereus 21 Third line 2 y y PR PD 8 12
Abbreviations: LUMC = Leiden University Medical Center; UMCG = University Medical Center Groningen; WHO = World Health 
Organisation; FIGO = International Federation of Gynecology and Obstetrics; CA: cancer antigen; CR; complete response; SD: stable 
disease; PR: partial response; PD: progressive disease; PFS: time from start therapy till progression of disease; OS: time form start 
therapy till death; na: not available; nd: not detectable WHO at inclusion; FIGO stage at diagnosis; Time defines time from diagnosis 
until inclusion (weeks)
Italic reflect patients with only a blood sample at baseline, and therefore not suitable for immunomonitoring
‡patient received only 1 dose of Peg-Intron
¥patient received only 1 vaccination
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Table 2: Adverse events
Adverse events Gemcitabine 
n = 3
Gemcitabine + Pegintron 
n = 9
Gemcitabine + Pegintron 
+ p53 SLP® n = 6




Dyspnea 1 1 1
Grade 1/2 Adverse Events in > 15% of patients
Fatigue 3 7 4
Flu-like symptoms 1 7 5
Nausea/Vomiting 2 6 4
Constipation 1 5 3
Diarrhea 3 1
Anorexia 3 4 1
Abdominal pain 2 1
Blood Chemistry Adverse Events Grade 3
Hypokalemia 1
Hyperkalemia 1
Local adverse events Gemcitabine + Pegintron Gemcitabine + Pegintron + p53 SLP®






>2 months  
n = 11
Swelling 0 (0%) 0 (0%) 11 (100%) 9 (82%)
<5 cm 4 (36%) 2 (18%)
5-10cm 4 (36%) 4 (36%)
>10cm 3 (27%) 3 (27%)
Erythema 0 (0%) 0 (0%) 11 (100%) 9 (82%)
mild 8 (73%) 8 (73%)
moderate 3 (27%) 1 (9%)
severe 0 (0%) 0 (0%)
Temperature 0 (0%) 0 (0%) 11 (100%) 0 (0%)
mild 2 (18%) 0 (0%)
moderate 7 (64%) 0 (0%)
severe 2 (18%) 0 (0%)
Pain 0 (0%) 0 (0%) 4 (36%) 2 (18%)
mild 4 (36%) 2 (18%)
moderate 0 (0%) 0 (0%)





vomiting (67%). Flu-like symptoms were observed 24 
hours after injection of Pegintron in 12 of 13 patients. 
All other systemic adverse events occurring in > 15% 
of all patients are summarized in Table 2A and did not 
significantly differ between the treatment groups. All 
patients who received the p53 SLP vaccine developed 
grade 1–2 local skin reactions with redness and induration 
at the injection sites (Table 2B). This toxicity was 
long-lasting because 82% of the vaccination sites still 
were swollen and red (grade 1–2; Example shown in 
Supplementary Figure S2) after 2 months.
Clinical outcome
A median of three gemcitabine cycles 
was administered (range 1 to 6). Fourteen patients did not 
complete all 6 chemotherapy cycles due to prog ression 
of disease. Based on CT-scan, a partial response (PR) 
was observed in two patients, stable disease (SD) in four 
patients and progressive disease (PD) in 10 patients. Two 
patients did not have a second CT-scan due to clinical PD. 
Outcome established by CA-125 levels resulted in one 
complete remission, three PR, two SD and six patients 
with PD. In five patients, CA-125 was not available, in 
one patient CA-125 was not evaluable.
Immunogenicity
Gemcitabine reduces MDSCs and increases M1, but 
not M2 macrophages
In order to investigate the immunological effects of 
this triple treatment regimen, we studied the changes in 
phenotype of different immune cells. Although patients 
displayed lower frequencies of total number of T-cells and 
higher frequencies of CD25posCD127lowFoxP3pos Tregs at 
baseline compared to healthy subjects, no changes in the 
frequencies of B cells, T-cells and Tregs were observed in 
response to the treatment. The total frequency of myeloid 
cells, defined by CD45+CD3-CD19- cells, was higher 
at baseline when compared to healthy donors but not 
affected by the treatment. Figure 2 shows the effect on all 
patients; Figure 3 shows the effect divided per treatment 
group. To get more insight in the effect of treatment on 
different subsets of the myeloid cell compartment, we 
analyzed the different subsets of MDSCs (HLA-DR- 
myeloid cells) and macrophages (HLA-DR+ myeloid 
cells). A classification of myeloid cell types based on our 
gating strategy (Supplementary Figure S1b) is shown in 
Supplementary Figure S3. Interestingly, the percentage 
of total HLA-DR + myeloid cells was increased upon 
treatment (p = 0.04; Figure 2D, Supplementary Figure S4), 
reflected by increases in CD11b+CD14+CD11c+CD163−
CD16−CD206− macrophages (macrophage type 6; 
potentially M1 macrophages; p = 0.04), but not of 
CD11b+CD14+CD11c+CD163+CD16−CD206− macro 
phages (macrophage type 8; suppressive M2-like 
macrophages; Figure 2E, 2F, Supplementary Figure 
S4). Concomitantly, an explicit decline in HLA-DR- 
myeloid cells (p = 0.0003) was observed (Figure 2G, 2H, 
Supplementary Figure S4), in particular that of CD14−
CD15−CD11b+CD33−CD34−CD124− (MDSC type 36; 
MDSC definition 10; p = 0.0005) in all treatment groups. 
The observed changes were found in all treatment groups 
(Figure 3, Supplementary Figure S5), suggesting that these 
effects are gemcitabine mediated.
Gemcitabine/Pegintron/p53 SLP treatment induces 
profound T-cell activation and increases in Activated 
T-cell/regulatory T cell ratios
In addition, the effect of treatment on the 
activation status of T-cells was studied. No changes 
in expression of CTLA-4 and CD45RA expression 
were observed in CD4+ and CD8+ T-cells and Tregs 
following treatment (not shown). Ki67 expression was 
detected in CD4+ Tregs, CD4+ non-Tregs and CD8+ 
T-cells, with Tregs displaying the highest percentages. 
Upon treatment Ki67 expression was significantly 
Local adverse events Gemcitabine + Pegintron Gemcitabine + Pegintron + p53 SLP®






>2 months  
n = 11
Itching 0 (0%) 0 (0%) 3 (27%) 2 (18%)
mild 3 (27%) 0 (0%)
moderate 0 (0%) 0 (0%)
severe 0 (0%) 0 (0%)
Ulceration 0 (0%) 0 (0%) 0 (0%) 0 (0%)
A) Adverse events, subdivided in different treatment groups. All grade 3/4 adverse events, adverse events occurring 
in more than 15% of all patients and blood chemistry adverse events > grade 2 are shown.B) Local adverse events at 
injection site. Adverse events at injection site were scored every visit and are subdivided here in early (after 1 week) 
and late (after 2 months) effects.
B.
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Figure 2: Phenotypical changes of different immune subsets upon treatment. The immune cell composition was measured 
by flow cytometry at baseline, after 2 cycles and end of study. Depicted here are the following cell subsets: A. B-cells B. T-cells C. Tregs 
D. HLA-DR+ myeloid cells E. M1 macrophages F. M2 macrophages G. HLA-DR- myeloid cells H. MDSC #36. Treatment induces an 
increase in HLA-DR+ cells and M1 macrophages, HLA-DR- cells were decreased (p = 0.0003) and in particular myeloid cell population 
type 36 (p = 0.0005; defined as CD45+CD3−CD19−HLA−DR−CD11b+CD33−CD34−CD124−CD15−CD14−).
Oncotarget32237www.impactjournals.com/oncotarget
up-regulated in CD4+ and CD8+ T-cells but not 
in Tregs, resulting in increased CD8+Ki67+ and 
CD4+Ki67+ (activated T-cell) to Ki67+ (activated) 
Treg (Tact/Treg) ratios (Figure 4). Interestingly, these 
increases were observed whenever patients were 
treated with gemcitabine and IFN-α, irrespective of p53 
vaccination (Figure 5).
Strength of immune response correlates with swelling 
of the injection site
Cellular immune responses to the vaccine were 
assessed by an IFN-γ ELISPOT assay. At baseline, 
only one patient (C13) displayed a T-cell response to 
p53 peptide pool3. Control patients, receiving only 
chemotherapy, did not show a response to any of the 
Figure 3: Phenotypical changes of different immune subsets upon treatment, divided per treatment group. The immune 
cell composition as measured by flow cytometry is given for each of the three different treatment groups. A. B-cells B. T-cells 
C. Tregs D. HLA-DR+ myeloid cells E. M1 macrophages F. M2 macrophages G. HLA-DR- myeloid cells H. MDSC #36. In 
all treatment groups, including group 1 receiving only gemcitabine, HLA-DR- myeloid cells and MDSC #36 are decreased, 
suggesting that gemcitabine is responsible for the decrease of MDSCs after 2 cycles of chemotherapy.
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p53 peptide pools in this assay. In the gemcitabine and 
Pegintron treatment group, two patients displayed 
a modest response after 2 cycles of treatment. P53-
specific T-cell responses were detectable in all p53 SLP 
vaccinated patients after treatment (p = 0.03; Figure 6A, 
Supplementary Figure S6). The general T-cell response, 
i.e. the recall response to influenza virus M1 peptides as 
well as to a mix of bacterial antigens (MRM), showed a 
non-significant increase in reactivity in patients treated 
with gemcitabine and Pegintron, irrespective of p53 
vaccination (Figure 6B). Interestingly, the magnitude of 
the swelling of the injection site was correlated with more 
IFN-γ producing p53-specific T-cells (p = 0.02; r = 0.87; 
Figure 6C).
Cytokine production and antigen presentation does not 
change upon treatment
The capacity of T-cells to proliferate upon 
antigenic stimulation was analyzed before and after 
treatment (Supplementary Figure S7A). Based on the 
amounts of cytokines secreted, the patients displayed a 
more pronounced Th1 profile, with high levels of IFN-γ 
and TNF-α rather than IL-4 or IL-5 (Supplementary 
Figure S7B). Neither the amount of cytokines produced 
nor the balance between the cytokines changed 
during treatment. In addition, there were no changes 
in the capacity of circulating antigen presenting 
cells to stimulate allogeneic lymphocyte reactions 
(Supplementary Figure S7C).
DISCUSSION
Patients with platinum-resistant p53-positive ovarian 
cancer were treated with gemcitabine, gemcitabine with 
Pegintron, or a combination of gemcitabine, Pegintron 
and p53 SLP vaccine. The combination treatments were 
safe, feasible and had immune stimulatory effects. Our 
results show that gemcitabine treatment resulted in a 
reduction of immune-suppressive MDSCs and an increase 
in immune-stimulating M1 macrophages. Furthermore, 
the combination of gemcitabine and Pegintron stimulated 
higher frequencies of circulating proliferating T-cells but 
Figure 4: Changes in Ki67 expression on different cell subsets upon treatment. Activation status of different T-cell subsets, 
as defined by Ki67+, was measured by flow cytometry at baseline, after 2 cycles and at end of study. A. The % of activated Tregs upon 
treatment. B. The percentage of activated CD8+ cells increases upon treatment (p = 0.05). C. Activated CD4+ T-cells are increased after 
therapy (p = 0.03). D. Activation status of CD4+ Tregsshowing less activated cells in patients compared to healthy donors. E. The ratio 
between activated CD8+ T-cells and activated Tregs increases upon treatment with the the balance in favor of activated CD8+ T-cells. F. The 
ratio between activated CD4+ T-cell and activated Tregs is in favor of the activated CD4+ T-cell.
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not Tregs. Moreover, all vaccinated patients showed a 
strong vaccine-induced p53-specific T-cell response.
We observed eleven grade 3/4 adverse events, most 
likely due to chemotherapy and/or Pegintron. To address 
the role of the combination of gemcitabine with Pegintron 
in bone marrow depletion would have required a group 
of patients treated with chemotherapy and vaccination 
only but such a group was not included because of the 
beneficial immunological effects of Pegintron on the 
T-cell response induced by the p53 SLP vaccine [24]. 
Pegintron-specific adverse events were flu-like symptoms 
reported within 24 hours after administration, but all were 
well manageable. Specific adverse events caused by the 
vaccine treatment were local redness and induration at 
the injection site which did not exceed grade 2 reactions. 
The observed skin reactions are in accordance with our 
previous study in which Pegintron was combined with the 
p53 SLP vaccine [24], and probably the result of a strong 
IFN-α potentiated (18–20, 27–29) immune response to 
the vaccine. This notion is strengthened by the explicit 
correlation between the size of the injection site (Figure 
4D) and the response measured by ELISPOT (Figure 4A), 
as well as the presence of circulating Ki67+ T-cells in 
patients treated with gemcitabine and Pegintron (Figure 3).
Several mouse studies showed that gemcitabine 
is able to eliminate MDSCs and Tregs [15–18]. We are 
the first to show in humans that gemcitabine treatment 
decreases MDSC, in particular the CD11b+, HLA-
DRlow (MDSC 10) population in humans (p = 0.0005). 
In addition, we showed that gemcitabine treatment 
resulted in an increase in M1 macrophages (p = 0.04) but 
importantly not in immune-suppressive M2 macrophages. 
Previously, it was shown that the population of circulating 
CD4+ Tregs displayed a higher proportion of ki67+ cells 
than non-Treg CD4+ T-cells or CD8+ T-cells [18]. Our 
study shows similar data on ki67 expression by T-cells. 
Of note, the small population study size makes the 
interpretation of the immunological data prone to false 
positive findings but it is encouraging to see that our data 
confirms the earlier findings in mouse models and patients 
Figure 5: Changes in Ki67 expression on different cell subsets upon treatment, divided per treatment group. Activation 
status of different T-cell subsets upon treatment, measured on baseline, after 2 cycles and at end of study. A. IIncreased – measured as an 
absolute shift – Ki67 expression in CD4+ (p = 0.02) and CD8+ cells (p = 0.01), but not on Tregs. B-D. Patients receiving gemcitabine, 
Pegintron and p53 SLP vaccination show increased Ki67 expression after 2 cycles of treatment by CD8+ T-cells (B), CD4+ T-cells (C) and 
by Tregs (D). E–F. The ratio between activated CD8+ or CD4+ T-cells and activated Tregs indicate a stronger increase in activated CD8+ 
cells (E), and non-Treges CD4+ T-cell (F).
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Furthermore, it was shown that gemcitabine treatment 
depleted the majority of the Ki67+ cells, when measured 
1–2 days after treatment, thereby disproportionally 
affecting Tregs [18]. We analyzed blood samples 7–14 
days after gemcitabine treatment and although we did 
not observe a decrease in the frequency of Ki67 + T-cells 
at that time point, a significant increase in Ki67+ CD4+ 
and CD8+ T-cells was detected, which was not mirrored 
by the CD4 + Treg population. This resulted in increased 
Ki67 + T-cell over Ki67+ Treg ratio’s, sustaining the 
notion that gemcitabine may affect Tregs more than other 
T-cells in humans even after the immediate effect of the 
drug has worn off.
Previous studies have shown that p53 SLP vaccination 
induced p53-specific T-cell responses in ovarian cancer 
patients [22] and that the combination with Pegintron 
resulted in stronger immune responses [24]. Here, the 
combination of Pegintron and p53 SLP resulted in a strong 
immune response reflected by the local vaccine site reactions 
and the T-cell response against the vaccine peptides as 
measured by IFN-γ ELISPOT assay. Compared to previous 
studies, concurrent administration of at least two cycles of 
gemcitabine does not affect p53-specific T-cell reactivity. 
Potentially this is also true for 6 cycles of gemcitabine but 
the number of patients tested at that point was too low for 
firm conclusions. It is important to emphasize that in the 
Figure 6: Strong p53-specific immune responses were measured after vaccination in combination with Pegintron. Cellular 
immune responses to the vaccine were assessed by an IFN-γ ELISPOT assay. A. Mean response against p53 divided per study group. 
Vaccinated patients show a strong response after vaccination (p = 0.03). No changes were observed in the T-cell response to B. the recall 
antigen mix MRM or C. influenza M1 (Flu). D. Swelling of injection site correlates with strength of T-cell response measured by IFN-γ 
ELISPOT (p = 0.02), measured by linear regression (r = 0.87).
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current study, there is no separate group combining p53 SLP 
vaccination with chemotherapy alone to study the influence 
of Pegintron on the p53-specific reactivity.
The combination of gemcitabine and IFN-α was 
shown to act synergistically in inhibiting tumor cell 
proliferation in a mouse model for pancreatic cancer 
[38, 39]. In a dose-finding phase 1 trial, Fuxius et al [40] 
combined gemcitabine at maximum tolerated dose (MTD) 
1000 mg/m2 with IFN-α-2b 3 × weekly (MTD 5 × 106 IU) 
for 3 consecutive weeks followed by 1 week of rest (28-day 
cycles) in patients with solid tumors, including one patient 
with ovarian cancer. This dose of IFNα is much higher 
than what we have used because our primary goal was to 
boost the immune response. The regimen was safe and 
associated with clinical data worth further investigations. 
Unfortunately, no immune monitoring was performed that 
would allow further comparison with our study.
This is a small dose finding study, and therefore 
underpowered to demonstrate efficacy in this challenging 
populationHowever, this study showed that gemcitabine 
treatment, immune modulation with Pegintron and 
therapeutic vaccination is a well-tolerated approach in 
the development of combined chemo-immunotherapeutic 
regimens to treat cancer. Gemcitabine may be administered 
as part of the standard of care, such as in this study, but can 
also be used in combination with T-cell stimulatory based 
immunotherapeutic strategies for its ability to decrease the 
number of immune suppressive in future studies.
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